Human Chorionic Gonadotropin Has Anti-Inflammatory Effects at the Maternal-Fetal Interface and Prevents Endotoxin-Induced Preterm Birth, but Causes Dystocia and Fetal Compromise in Mice

Amy-Eunice Furcron, Roberto Romero, Tara N. Mial, Amapola Balancio, Bogdan Panaitescu, Sonia S. Hassan, Aashah Sabi, Claire Nord, and Nardyhy Gomez-Lopez

Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, and Detroit, Michigan
Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan
Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan
Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan
Center for Molecular Obstetrics and Genetics, Wayne State University, Detroit, Michigan
Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan

ABSTRACT

Human chorionic gonadotropin (hCG) is implicated in the maintenance of uterine quiescence by down-regulating myometrial gap junctions during pregnancy, and it was considered as a strategy to prevent preterm birth at the occurrence of preterm labor. However, the effect of hCG on innate and adaptive immune cells implicated in parturition is poorly understood. Herein, we investigated the immune effects of hCG at the maternal-fetal interface during late gestation, and whether this hormone can safely prevent endotoxin-induced preterm birth. Using immunophenotyping, we demonstrated that hCG has immune effects at the maternal-fetal interface (decidual tissues) by: 1) increasing the proportion of regulatory T cells; 2) reducing the proportion of macrophages and neutrophils; 3) inducing an M1 → M2 macrophage polarization; and 4) increasing the proportion of T helper 17 cells. Next, ELISAs were used to determine whether the local immune changes were associated with systemic concentrations of prostaglandin, estradiol, and/or cytokines (IFNγ, IL1β, IL2, IL4, IL5, IL6, IL10, IL12p70, KC/GRO, and TNFα). Plasma concentrations of IL1β, but not progesterone, estradiol, or any other cytokine, were increased following hCG administration. Treatment with hCG prevented endotoxin-induced preterm birth by 44%, proving the effectiveness of this hormone as an anti-inflammatory agent. However, hCG administration alone caused dystocia and fetal compromise, as proven by Doppler ultrasound. These results provide insight into the mechanisms whereby hCG induces an anti-inflammatory microenvironment at the maternal-fetal interface during late gestation, and demonstrate its effectiveness in preventing preterm labor/birth. However, the deleterious effects of this hormone on mothers and fetuses warrant caution.

decidua, estradiol, hCG, interleukin-1β, M1 macrophages, M2 macrophages, mouse, neutrophils, parturition, pregnancy, preterm labor, progesterone, regulatory T cells, Th17 cells

INTRODUCTION

Pregnancy maintenance involves endocrine interactions between the mother and fetus. The first hormone to participate in this interaction is human chorionic gonadotropin (hCG) [1–3]. Human CG is a complex glycoprotein composed of α and β glycosylated subunits [4], and is considered a superagonist of luteinizing hormone receptors [5]. Human CG is produced by the syncytiotrophoblast [6–8] and, to a lesser extent, by the invasive extravillous cytotrophoblast [8, 9]. Human CG receptors are expressed in reproductive tissues [2, 10, 11], fetal-placental tissues [12–14], and immune cells [15–17], indicating that this hormone has multiple targets, and is not only relevant to pregnancy initiation [18]. In line with this concept, hCG is involved in: 1) preserving the progesterone-producing corpus luteum [19]; 2) promoting angiogenesis [20, 21], trophoblast differentiation [22, 23], and maternal-fetal tolerance [24–28]; and 3) maintaining myometrial quiescence [29–35].

Maternal-fetal tolerance involves the function of regulatory T cells (Tregs) [36], dendritic cells (DCs) [37–41], B cells [42–44], and M2 or immunosuppressive macrophages [45–47]. During early pregnancy, hCG contributes to this tolerance by: 1) increasing the migration of Tregs into the maternal-fetal interface [26, 28]; 2) enhancing Treg frequencies in the circulation, lymphatic organs, and decidual tissues of abortion-prone mice (DBA/2-mated CBA females) [28]; 3) inducing Treg suppressive activity in vivo [28]; 4) stimulating IL10 production by circulating B cells [43]; and 5) driving a tolerogenic phenotype in bone marrow-derived DCs [48].
However, the effect of hCG on these immune cells during late gestation is poorly understood. Human CG was considered a vestigial hormone in late gestation [49]. This is due to the fact that systemic concentrations of hCG increase in the first trimester and reduce thereafter [50]. Furthermore, systemic concentrations of hCG significantly decrease 2–3 wk before labor [51], suggesting that decreasing concentrations of this hormone participate in the onset of parturition. We therefore hypothesize that the systemic administration of hCG will delay the onset of parturition.

Elucidating the role of pregnancy-related hormones in late gestation is relevant, since maternal-fetal tolerance, and therefore immune cells activity, is still required during this period. For example, the diminished suppressive function of Tregs is associated with spontaneous preterm labor/birth [52], and mice deficient in T and B cells (Rag1−/−) are more susceptible to endotoxin-induced preterm birth than wild-type mice [53]. In addition, a reduction of Tregs in the myometrial tissues is observed in wild-type mice prior to endotoxin-induced preterm birth [54]. Therefore, a breakdown of maternal-fetal tolerance during late gestation is considered a mechanism of disease for preterm labor [55, 56], which leads to preterm birth in 70% of cases [57]. Prematurity is the leading cause of perinatal morbidity and mortality worldwide [58], and represents a substantial burden for society and the healthcare system [59]. Hence, the prevention of preterm birth is a health care priority.

Herein, we hypothesize that pretreatment with a natural pregnancy hormone, hCG, fosters maternal-fetal tolerance during late gestation by favoring an anti-inflammatory microenvironment at the maternal-fetal interface, thereby preventing preterm birth.

The main aim of this study was to determine the effects of hCG on Tregs and other T cell subsets, macrophages, neutrophils, natural killer (NK) cells, as well as M1-like and M2-like macrophages in decidual tissues (maternal-fetal interface). The effect of hCG on the concentrations of progesterone, estradiol, and IL1β in maternal plasma was also determined. The effectiveness of hCG in preventing preterm birth was tested in mice injected with an endotoxin, and the safety of hCG was evaluated using in vivo imaging via ultrasound.

**MATERIALS AND METHODS**

**Animals**

C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and bred in the animal care facility at the C.S. Mott Center for Human Growth and Development at Wayne State University (Detroit, MI). All mice were kept under a circadian cycle (12L:12D). Females (8–12 wk old) were mated with males of the same phenotype. Female mice were checked daily between 0800 and 0900 h for the appearance of a vaginal plug, which indicated 0.5 days postcoitum (dpc). Females were then separated from males, their weight was monitored, and a gain of 21 g by 12.5 dpc confirmed pregnancy. All procedures were approved by the Institutional Animal Care and Use Committee at Wayne State University (protocol nos. A09-08-12 and A07-03-15).

**Human CG Administration**

Pregnant B6 females were intraperitoneally injected on 13.0, 15.0, and 17.0 dpc with 10 IU of hCG (Sigma-Aldrich, St Louis, MO) dissolved in 500 μl of 1× sterile PBS (Fisher Scientific Bioreagents, Fair Lawn, NJ) or 500 μl of PBS alone as a control, as previously described [28]. Prior to delivery (18.5 dpc), mice were euthanized, and the peripheral blood, lymphoid organs (the uterine-draining lymph nodes, thymus, and spleen), and decidual tissues were harvested (Fig. 1A). Leukocyte isolation was immediately performed on
lymphoid organs and decidual tissues, and plasma was separated for hormone and cytokine determination.

**Leukocyte Isolation**

Leukocytes were isolated from decidual tissues as previously described [60]. Briefly, decidual tissues were immersed in a cell-dissociating reagent (StemPro Accutase Cell Dissociation Reagent; Life Technologies, Grand Island, NY) and homogenized with a pair of small surgical scissors for 1–2 min. The homogenized tissue was incubated for 35 min at 37°C with gentle shaking (MaxQ 4450 Benchtop Orbital Shaker; Thermo Fisher Scientific, Marietta, OH). The cell suspension was washed with FACS buffer (bovine serum albumin 0.1% [Sigma-Aldrich], sodium azide 0.05% [Fisher Scientific (MaxQ 4450 Benchtop Orbital Shaker; Thermo Fisher Scientific, Marietta, OH)]. The cell suspension was washed with FACS buffer (bovine serum albumin 0.1% [Sigma-Aldrich], sodium azide 0.05% [Fisher Scientific, Hanover Park, IL]). Simultaneously, leukocytes were isolated from the uterine-draining lymph nodes, thymus, and spleen by gentle dissociation using two double-frosted glass micro slides (Corning Inc., Corning, NY). Both decidual and lymphoid cell suspensions were then centrifuged at 1300 × g at 4°C for 10 min, and the resulting cell pellet was used for immunophenotyping.

**Immunophenotyping**

Decidual and lymphoid cell suspensions were incubated with a mouse monoclonal CD16/CD32 antibody (FcγIII/II Receptor; BD Biosciences, San Jose, CA) at 4°C for 10 min. Next, cell suspensions were incubated at 4°C with extracellular and/or intracellular conjugated antibodies (Supplemental Table S1; available online at www.bioreprod.org) for 30 min in the dark. Two groups of mice were used for immunophenotyping. In the first group, mice were injected with PBS or hCG (n = 8–10 each), and proportions of Tregs (CD3+Foxp3+ T cells) were determined in the decidual, spleen, thymus, and uterine-draining lymph nodes. Macrophages (CD45+F4/80+ cells), neutrophils (CD45+Ly6G- cells), and NK cells (CD45+CD49b+ cells) were also determined in decidual tissues. In the second group, mice were injected with PBS or hCG (n = 10 each), and proportions and numbers of M1-like (CD11b+Ly6G F4/80 IFNγ+ and/or iNOS+ cells) and M2-like (CD11b+Ly6G F4/80 Arg1+ and/or IL10+ cells) macrophages, T helper (Th) 1 (CD4+IL2, IL4, IL5, IL6, IL10, IL12p70, KC/GRO, and TNFα), Th2 (CD4+IL4, IL10, Th9 (CD3+CD4+IL10+), Th9 (CD3+CD4+IL9+), and Th17 (CD3+CD4+IL17a+ cells) cells were determined in decidual tissues.

Nuclear staining of Foxp3 was performed using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA), and intracellular cytokine staining was performed using the Cytofix/Cytoperm Fixation and Permeabilization Buffer Kit (BD Biosciences), according to the manufacturer’s protocols. Finally, cell suspensions were acquired using the LSRFortessa Flow Cytometer (BD Biosciences) and analyzed using BD FACSDiva Software Version 8.0 (BD Biosciences). The figures were prepared using FlowJo Software Version 10 (FlowJo, LLC, Ashland, OR).

**Enzyme-Linked Immune Assays**

Plasma concentrations of progesterone and estradiol were determined using the PROG-EASIA ELISA kit (GenWay Biotech, Inc., San Diego, CA) and the Calbiotech Mouse/Rat Estradiol ELISA kit (Calbiotech Inc., Spring Valley, CA), according to the manufacturers’ instructions. Plasma concentrations of IFNγ (IL1β), IL2, IL4, IL5, IL6, IL10, IL12p70, KC/GRO, and TNFα were assessed using sensitive and specific immunoassays according to the manufacturer’s instructions (V-PLEX Prolinflammatory Panel 1 Kit; Mesoscale Discovery, Gaithersburg, MD). The sensitivities of the assays were: 0.04 pg/ml (IFNγ), 0.11 pg/ml (IL1β), 0.22 pg/ml (IL2), 0.14 pg/ml (IL4), 0.07 pg/ml (IL5), 0.61 pg/ml (IL6), 0.95 pg/ml (IL10), 0.05 pg/ml (IL12p70), 0.24 pg/ml (KC/GRO), and 0.13 pg/ml (TNFα); and the interassay and intra-assay coefficients of variation were below 15% and 7%, respectively.

**Endotoxin-Induced Preterm Birth in Mice Pretreated with hCG**

Pregnant B6 females were injected as follows: 1) PBS alone (n = 10); 2) hCG alone (n = 7); 3) hCG + endotoxin (n = 11); and 4) endotoxin alone (n = 10). Groups 1, 2, and 3 were injected on 13.0, 15.0, and 17.0 dpc. On 16.5 dpc, groups 3 and 4 were intraperitoneally injected with 10 μg of an endotoxin (Escherichia coli; 055:B5; Sigma-Aldrich) in 200 μl of PBS. Between 16.5 and 17.0 dpc, mice were placed for video recording in order to determine gestational age, duration of labor, and the rates of stillbirth and preterm birth. Gestational age was defined as the time elapsed from the delivery of the first pup through the delivery of the last pup. Rate of stillbirth was defined as the percentage of pups found dead among the total litter size. Preterm birth was defined as all deliveries occurring prior to 18.0 dpc, and its rate was represented by the percentage of females delivering preterm among those delivering at term (19.5 ± 0.5 dpc). Dystocia was defined as disturbed progression of labor (duration of labor > 6 h), and its rate was represented by the percentage of females in dystocia among those delivering successfully.

**In Vivo Imaging by Ultrasound**

Pregnant B6 mice were injected with PBS or hCG on 13.0, 15.0, and 17.0 dpc, as previously described (n = 4–5 each) [60]. On 18.5–19.5 dpc, pregnant B6 mice were anesthetized by inhalation of 2%–3% isoflurane (Aerrane; Baxter Healthcare Corp., Deerfield, IL) and 1–2 L/min of oxygen in an induction chamber. Anesthesia was maintained with a mixture of 1.5%–2% isoflurane and 1.5–2 L/min of oxygen. Dams were positioned on a heating pad and stabilized with adhesive tape. Fur was removed from the abdomen and thorax after Nair cream (Church & Dwight Co., Inc., Ewing, NJ) was applied to the area. Body temperature was maintained in the range of 37 ± 1°C and detected with a rectal probe. Respiratory rate and heart rate were monitored by electrodes embedded in the heating pad. An ultrasound probe was fixed and mobilized with a mechanical holder, and the transducer was slowly moved toward the abdomen. Fetal heart rate and umbilical artery pulsatility indexes. Fisher exact tests were used to compare the rates of preterm birth and dystocia between groups. A P value of <0.05 was considered statistically significant.

**RESULTS**

**Administration of hCG Increases the Proportion of Decidual Tregs**

First, we determined whether hCG administration increased the proportion of Tregs, a T cell subset that participates in maternal-fetal tolerance [25, 36], in decidual tissues and lymphatic organs. Figure 1B shows the gating strategy used to identify Tregs in decidual tissues. Pregnant mice injected with hCG had higher proportions of decidual Tregs than control mice injected with PBS (Fig. 1C). In contrast, hCG administration did not alter the proportion of Tregs in the thymus, spleen, or uterine-draining lymph nodes when compared to control mice (Fig. 2). These results demonstrate that hCG administration from mid- to late gestation increases Tregs at the maternal-fetal interface.

**Administration of hCG Decreases the Proportion of Macrophages and Neutrophils in Decidual Tissues**

Next, we investigated whether hCG administration altered the proportion of macrophages, neutrophils, and NK cells in decidual tissues, all of which participate throughout pregnancy and/or parturition [56, 62, 63]. The gating strategy used to identify macrophages, neutrophils, and NK cells is shown in Figure 3A. Pregnant mice injected with hCG had lower proportions of decidual macrophages (Fig. 3B) and neutrophils (Fig. 3C) than control mice. However, hCG administration did not alter the proportions of NK cells in decidual tissues (data not shown). These data show that hCG administration from...
mid- to late gestation reduces the proportion of innate immune cells, which are known to have proinflammatory roles at the maternal-fetal interface.

Administration of hCG Induces an M1 → M2 Macrophage Polarization in Decidual Tissues

The current hypothesis states that decidual M2-polarized macrophages are implicated in supporting maternal-fetal tolerance throughout pregnancy [46, 47], and that during parturition, these cells shift to a proinflammatory phenotype [64]. Here, we investigated whether hCG induces an M1 → M2 macrophage polarization in decidual tissues. The gating strategy used to characterize M1-like and M2-like macrophages in decidual tissues is shown in Figure 4A. Pregnant mice injected with hCG had lower numbers of IFNγ+ M1-like macrophages (Fig. 4B), but higher numbers of Arg1+ M2-like macrophages (Fig. 4C) when compared to control mice. No differences between groups were observed in iNOS+ M1-like macrophages or IL10+ M2-like macrophages (data not shown). These results show that hCG can induce an anti-inflammatory microenvironment by inducing an M1 → M2 macrophage polarization at the maternal-fetal interface.

Administration of hCG Increases the Proportion of Th17 Cells in Decidual Tissues

Since hCG administration induced macrophage polarization, we next investigated whether this hormone would induce Th cell differentiation in decidual tissues. The gating strategy used to determine Th1, Th2, Th9, and Th17 cells in decidual tissues is shown in Figure 5A. Pregnant mice injected with hCG had higher proportions of decidual Th17 cells than control mice (Fig. 5B). No changes were observed in Th1, Th2, or Th9 cells in decidual tissues upon hCG administration (data not shown). These data demonstrate that hCG administration from mid to late gestation induces a Th17 cell polarization at the maternal-fetal interface, but does not alter other Th cell subsets.

Administration of hCG Does Not Change the Plasma Concentrations of Progesterone and Estradiol

In vivo and in vitro studies have demonstrated that hCG stimulates the production of progesterone and estrogen [65, 66]. Therefore, we investigated whether in vivo administration of hCG from mid- to late gestation would change the systemic concentrations of progesterone and/or estradiol. Human CG did not change the plasma concentrations of progesterone or estradiol (Fig. 6, A and B). These results show that the local anti-inflammatory effect of hCG at the maternal-fetal interface is not associated with systemic concentrations of progesterone and estradiol.

Administration of hCG Increases the Plasma Concentration of IL1β

Next, we investigated whether hCG administration would change the systemic concentrations of pro- and anti-inflammatory cytokines. Human CG administration from mid- to late gestation increased the plasma concentration of IL1β (Fig. 6C). However, no differences were observed in the systemic concentrations of IFNγ, IL2, IL5, IL6, KC/GRO, IL10, or TNFα between mice injected with hCG and those injected with PBS (data not shown). Concentrations of IL4 and IL12p70 were undetectable in plasma samples. Our data suggest that, although hCG has anti-inflammatory effects at the maternal-fetal interface, this hormone may have proinflammatory effects in maternal circulation.

Pretreatment with hCG Reduces the Rate of Endotoxin-Induced Preterm Birth

To evaluate the effectiveness of hCG in the prevention of endotoxin-induced preterm birth, pregnant mice were pretreated with hCG and then injected with an endotoxin. Mice pretreated with hCG had a reduced rate of endotoxin-induced preterm birth when compared to control mice injected with endotoxin alone (36.3 ± 28.4% [4/11] vs. 80 ± 24.7% [8/10]; P = 0.04; Table 1). However, pretreatment with hCG did not reduce the rate of stillbirth in mice injected with an endotoxin (85.2 ± 8.9% [52/61] vs. 100% [70/70]; Table 1). Human CG administration to endotoxin-injected mice led to an increased rate of dystocia when compared to PBS controls (36.3 ± 28.4% [4/11] vs. 0%; P = 0.03; Table 1). This was likely due to hCG, since its administration alone delayed parturition and caused dystocia in all cases without inducing preterm birth (Table 1). These results demonstrate that pretreatment with hCG from mid- to late gestation reduced the rate of endotoxin-induced preterm birth, yet caused dystocia.
Human CG Administration Does Not Cause Fetal Death, but Induces Fetal Compromise

All dams injected with hCG underwent dystocia (Table 1), and delivered hypoxic/dead pups (Fig. 7A). This is not surprising, since animals that undergo dystocia deliver dead pups due to complications during the process of labor [67]. In our study, however, another possibility was that hCG had adverse effects on fetuses (in utero), rather than in pups (after delivery). Since abnormal umbilical artery velocimetry and fetal heart rate are associated with fetal compromise [68, 69], Doppler ultrasound was performed in dams injected with hCG or PBS (controls). Fetuses from mice injected with hCG were alive, but umbilical artery pulsatility indexes and fetal heart rates were abnormal compared to those from mice injected with PBS (Fig. 7, B and C). These data demonstrate that, although hCG does not cause fetal death, it causes dystocia and fetal compromise.

DISCUSSION

In the present study, we demonstrated that hCG administration has anti-inflamatory effects at the maternal-fetal interface (decidual tissues) by: 1) increasing the proportion of Tregs; 2) reducing the proportion of macrophages and neutrophils; and 3) inducing an M1 → M2 macrophage polarization. Human CG also increased the proportion of decidual Th17 cells. These local changes were not associated with increased systemic concentrations of progesterone or estradiol; however, they were linked to an increased plasma concentration of IL1β. Although pretreatment with hCG prevented endotoxin-induced preterm birth (effect size 44%; P = 0.04), it caused dystocia and fetal compromise.

A Role for hCG in Maternal-Fetal Tolerance During Late Gestation

Tregs are a subset of T cells expressing the activation marker CD25 and the transcriptional factor Foxp3 [70–73]. These cells play a central role in immune responses through their suppressive activity of both self- and non-self-antigens [74], and their function is largely due to the expression of Foxp3 [71, 75]. The most recent hypothesis states that there is an expansion of Tregs during coitus and implantation [76–78], which is maintained throughout gestation in order to sustain a full-term pregnancy [36, 52, 79]. We recently demonstrated that the local administration of progesterone, a hormone produced by the placenta [80], as is hCG [6–9], induces an
expansion of Tregs at the maternal-fetal interface [81]. In the present study, an expansion of decidual Tregs in late gestation was observed following hCG administration. This is consistent with previous studies demonstrating that hCG recruits Tregs into the maternal-fetal interface during early pregnancy [26, 28]. In accordance with one of the aforementioned studies [28], we did not observe an expansion of Tregs in the lymphatic organs of MHC-compatible mated mice. Together, these results demonstrate that hCG causes an increase of Tregs in early and late gestation.

In addition to Tregs, immunoregulatory or M2-polarized macrophages also participate in maternal-fetal tolerance [45–47]. M2-polarized macrophages induce homeostasis, dampen inflammation, and promote tissue remodeling and tumor progression [82–84]. M2-polarized macrophages also exhibit an increase in phagocytic activity and express scavenging mannose and galactose receptors, as well as a high production of ornithine and polyamines through the arginase pathway [85, 86]. Recently, we demonstrated that decidual M2-like macrophages (CD11b⁺ F4/80⁺ Arg1⁺ or IL10⁺ cells) are abundant at the maternal-fetal interface prior to iNKT cell activation-induced preterm labor [60]. Our findings suggest that these cells can also have proinflammatory roles during parturition. In the present study, we demonstrated that hCG administration increases the number of decidual M2-like macrophages in late gestation. Together, these data suggest that hCG induces M2-like macrophages, which may participate in both maternal-fetal tolerance during late gestation and the process of term parturition.

A Role for hCG in Reducing the Proinflammatory Microenvironment at the Maternal-Fetal Interface During Late Gestation

Proinflammatory macrophages are present in reproductive tissues and at the maternal-fetal interface (decidual tissue) immediately before and during spontaneous term and preterm labor [64, 87–93]. Monocyte/macrophage function and infiltration can be regulated by hCG [94–96]; however, whether this hormone induces or reduces inflammation is controversial. For example, in vitro studies demonstrated that hCG increases the secretion of macrophage inhibitory factor in human endometrial cells [97] and granulosa cells [95]. This hormone also enhances the production of NO, ROS, IL6, IL12p40, and phagocytic function in bone marrow-derived macrophages [96], and promotes IL8 secretion by peripheral blood...
mononuclear cells from women in early pregnancy [98]. Conversely, an in vivo study demonstrated that pretreatment with hCG alleviates thioglycollate-induced peritonitis by reducing TNF-α, IL-6, pentraxin-related protein 3, CCL3, and CCL5 concentrations in peritoneal lavage fluid [99], which mainly contains macrophages. Here, we demonstrate that pretreatment with hCG from mid- to late gestation reduces the abundance of decidual M1-like macrophages, which provides further evidence of the anti-inflammatory role of this hormone at the maternal-fetal interface.

Neutrophils play an important role during pregnancy, as they release proinflammatory mediators that are associated with the onset of labor [87, 89, 100]. Specifically, in decidual tissues, neutrophils contribute to the proinflammatory micro-environment that accompanies labor during term and preterm gestations by releasing inflammatory cytokines and mediators, as well as matrix metalloproteinases (MMPs) [101–104]. Similar to macrophages, the effect of hCG on neutrophils is contradictory. In vitro studies have demonstrated that hCG is a chemoattractant for human blood neutrophils [94]; however, it was also shown that this hormone induces apoptosis [105] and inhibits phagocytosis and oxidative activity on these innate cells [106]. In this study, we demonstrated that pretreatment with hCG from mid- to late gestation reduces the frequency of decidual neutrophils, which supports the hypothesis that this hormone dampens inflammation at the maternal-fetal interface.

Human CG Administration Increases the Proportion of Th17 Cells in Decidual Tissues

In addition to regulating effector innate immune cells, such as neutrophils and macrophages, hCG can modulate effector T
TABLE 1. Pretreatment with hCG reduces the rate of endotoxin-induced preterm birth but causes dystocia.

| Parameter* | PBS only | Endotoxin only | Endotoxin + hCG | hCG only† | P value‡ |
|------------|----------|----------------|---------------|-----------|---------|
| No. of mice per group | 10   | 10              | 11            | 7         | NS      |
| Gestational age (days; median ± SEM) | 19.1 ± 0.09 | 17.5 ± 0.1 | 18.3 ± 0.8 | 22.5 ± 0.3 | *P < 0.001 |
| Duration of labor (min; median ± SEM) | 91 ± 10.4 | 90 ± 20.1 | 80 ± 15.2 | n/a | NS      |
| Rate of stillbirth (% ± 95% CI) | 9 ± 6.3 | 100           | 85.2 ± 8.9 | n/a | *P < 0.001 |
| Rate of preterm birth (% ± 95% CI) | 0   | 80 ± 24.7 | 36.3 ± 28.4 | 0         | *P < 0.001 |
| Rate of dystocia (% ± 95% CI) | 0   | 10 ± 18.5 | 36.3 ± 28.4 | 100 | *P = 0.03 |

* CI, confidence interval.
† n/a, not applicable.
‡ NS, not significant.
§ PBS vs. endotoxin.
¶ PBS vs. endotoxin + hCG.
∥ PBS vs. hCG.
¶ Endotoxin vs. endotoxin + hCG.
†† Endotoxin vs. hCG.
‡‡ hCG vs. endotoxin + hCG.

The Role of hCG in Preventing Endotoxin-Induced Preterm Birth, Inducing Systemic Inflammation, and Influencing Fetal Outcomes

Pilot studies have shown that hCG suppresses uterine contractions in women undergoing preterm labor, delaying delivery without causing fetal side effects [124, 125]. In addition, pretreatment with hCG delays the time of delivery in mice injected with prostaglandin F2α [126]. Consequently, administration of hCG has been suggested as a strategy for preterm labor prevention [49]. In the present study, we investigated the effectiveness of hCG in preventing endotoxin-induced preterm birth and its safety in pregnancy. Pretreatment with hCG prevents endotoxin-induced preterm birth by 44%. However, mice injected with hCG had high rates of dystocia and increased systemic concentrations of IL1β, which, in turn, can up-regulate the secretion of hCG by the placenta [127, 128]. These data suggest that this cytokine is implicated in the event of hCG-induced dystocia.

The fact that hCG administration increases the systemic concentrations of IL1β is in concordance with a previous study demonstrating that this hormone increases serum concentrations of IL1α and IL1β in patients undergoing in vitro fertilization-embryo transfer [129]. The systemic proinflammatory effect of hCG is not surprising, since this hormone can activate the immune system [96]. However, hCG has anti-inflammatory effects at the maternal-fetal interface. Taken together, these data suggest that this hormone has differential functionality on decidual and peripheral leukocytes. Given this differential functionality, it is tempting to suggest that the local administration (i.e., vaginally) of hCG could induce anti-inflammation at the maternal-fetal interface without causing systemic proinflammatory effects.

The present study also demonstrates that administration of hCG did not cause fetal death, yet caused fetal compromise, which supports previous animal studies demonstrating that this hormone negatively impacts fetal health [130, 131]. The adverse effect of hCG on fetal heart rate may be explained by the fact that this hormone is produced by the placenta and causes physiological changes in the fetus similar to those seen in the mother [132]. In the mother, hCG inhibits uterine contractility by decreasing intracellular free Ca2+ levels [30] which, in turn, could lead to myocardial ischemia and tissue injury [133]. These adverse effects are attributed to increased myocardial oxygen consumption, which occurs due to an increased heart rate, stroke volume, and cardiac output [133]. These findings warrant further study of the adverse effects of hCG on the process of labor and the offspring, prior to its implementation as a method for preventing preterm labor/birth.

In summary, the present study demonstrates that hCG administration induces an anti-inflammatory microenvironment at the maternal-fetal interface by increasing Tregs and M2-like macrophages, and by decreasing M1-like macrophages and neutrophils. Human CG administration also increased the proportion of decidual Th17 cells and plasma concentrations of IL1β; however, their roles require further investigation. These changes were not associated with systemic concentrations of progesterone and estradiol. Pretreatment with hCG reduced the rate of endotoxin-induced preterm birth without causing fetal death; however, this
hormone caused dystocia and fetal compromise. These results provide insight into the mechanisms whereby hCG induces an anti-inflammatory microenvironment at the maternal-fetal interface during late gestation and prevents preterm labor/birth. However, the fetal compromise induced by hCG may represent an alteration in the physiology of the fetus that could lead to neonatal mobility and/or mortality. The adverse effects of hCG in human pregnancy are unknown. Nevertheless, the deleterious effects of this hormone in this animal model warrant caution.

FIG. 7. The effects of hCG on fetuses. A) Uterine horns and fetuses from mice injected with PBS or hCG at 18.5 or 22.5 dpc, respectively. B and C) Doppler ultrasound was performed on fetuses at 18.5 dpc from mice injected with PBS or hCG. Umbilical artery pulsatility indexes and fetal heart rates were recorded. Data are from four to five independent litters.
ACKNOWLEDGMENT

We gratefully acknowledge Marcia Arenas-Hernandez, Akshata Naik, Derek Miller, Dr. Zhong Dong, Lorri McCluckie, and Roni Wang for their contributions to the execution of this study, and to Maureen McGerty and George Schwenkel for their critical readings of the manuscript.

REFERENCES

1. Reshef E, Lei ZM, Rao CV, Priddham DD, Chegini N, Luborsky JL. The presence of gonadotropin receptors in nonpregnant human uterus, human placenta, fetal membranes, and decidua. J Clin Endocrinol Metab 1990; 70:421–430.

2. Lei ZM, Reshef E, V. The expression of human chorionic gonadotropin/luteinizing hormone receptors in human endometrium and myometrial blood vessels. J Clin Endocrinol Metab 1992; 75:651–659.

3. Fournier T, Guibourdenche J, Evain-Brion D. Review: hCGs: different sources of production, different glycoforms and functions. Placenta 2015; 36(suppl 1):S60–S65.

4. Boorstein WR, Vamvakopoulos NC, Fiddes JC. Human chorionic gonadotropin beta-subunit is encoded by at least eight genes arranged in tandem and inverted pairs. Nature 1982; 300:419–422.

5. Dufau ML. The luteinizing hormone receptor. Annu Rev Physiol 1998; 60:461–496.

6. Hoshina M, Hussa R, Patillo R, Camel HM, Boone I. The role of trophoblast differentiation in the control of the hCG and hPL genes. Adv Exp Med Biol 1984; 176:299–312.

7. Muyan M, Boone I. Secretion of chorionic gonadotropin from human trophoblasts. Placenta 1997; 18:237–241.

8. Kovalevskaia G, Genbacev O, Fisher SJ, Caceres E, O’Connor JF. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002; 194:147–155.

9. Handschuh K, Guibourdenche J, Tsatsaris V, Guesnon M, Laurendeau I, Evin-Brioin D, Fournier T. Human chorionic gonadotropin expression in human trophoblasts from early placenta: comparative study between villous and extravillous trophoblastic cells. Placenta 2007; 28:175–184.

10. Lin PC, Li X, Lei ZM, Rao ChV. Human cervix contains functional luteinizing hormone/human chorionic gonadotropin receptors. J Clin Endocrinol Metab 2001; 86:3409–3414.

11. Phillips RJ, Tyson-Capper Nee Pollard AJ, Bailey J, Robson SC, Europe-Connor J, van Kooyk Y, Kampgen E. Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of human pregnancy. Nat Immunol 2004; 5:266–271.

12. Licht P, Cao H, Lei ZM, Rao CV, Merz WE. Novel self-regulation of human chorionic gonadotropin in differentiation of human cytotrophoblasts. Endocrinology 1993; 133:3014–3025.

13. Toth P, Li X, Lei ZM, Rao CV. Expression of human chorionic gonadotropin/luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes. J Clin Endocrinol Metab 1994; 79:907–911.

14. Slattery MM, Banneman C, O’Leary MJ, Morrison JJ. Human chorionic gonadotropin inhibition of pregnant human myometrial contractility. BJOG 2001; 108:704–708.

15. Doheny HC, Houlihan DD, Ravikumar N, Smith TJ, Morrison JJ. Human chorionic gonadotropin relaxation of human pregnant myometrium and activation of the BKCa channel. J Clin Endocrinol Metab 2003; 88:4310–4315.

16. Belmonte A, Ticconi C, Dolci S, Giorgi M, Zicari A, Lenzi A, Jannini EA, Piccione E. Regulation of phosphodiesterase 5 expression and activity in human pregnant and non-pregnant myometrial cells by human chorionic gonadotropin. J Soc Gyneco Invest 2005; 12:570–577.

17. Ticconi C, Piccione E, Belmonte A, Rao ChV. HCG—a new kid on the block in prematurity prevention. J Matern Fetal Neonatal Med 2006; 19:247–155.

18. Handschuh K, Guibourdenche J, Tsatsaris V, Guesnon M, Laurendeau I, Evin-Brioin D, Fournier T. Human chorionic gonadotropin expression in human trophoblasts from early placenta: comparative study between villous and extravillous trophoblastic cells. Placenta 2007; 28:175–184.

19. Lin PC, Li X, Lei ZM, Rao ChV. Human cervix contains functional luteinizing hormone/human chorionic gonadotropin receptors. J Clin Endocrinol Metab 2001; 86:3409–3414.

20. Phillips RJ, Tyson-Capper Nee Pollard AJ, Bailey J, Robson SC, Europe-Connor J, van Kooyk Y, Kampgen E. Unique appearance of proliferating antigen-presenting cells expressing DC-SIGN (CD209) in the decidua of human pregnancy. Nat Immunol 2004; 5:266–271.
in antigen presentation severely restrict T cell recognition of the allogeneic fetus. J Clin Invest 2007; 117:1399–1411.
41. Bizgarty P, Bonney EA. Dendritic cells: a family portrait at midgestation. Immunology 2009; 126:565–578.
42. Jensen F, Muzzio D, Soldati R, Fest S, Zencussen AC. Regulatory B10 cells restore pregnancy tolerance in a mouse model. Biol Reprod 2013; 89:90.
43. Rolle L, Memzarzadeh Tehran M, Morell-Garcia A, Raeva Y, Schumacher A, Hartig R, Costa SD, Jensen F, Zencussen AC. Cutting edge: IL-10-producing regulatory B cells in early human pregnancy. Am J Reprod Immunol 2013; 70:448–453.
44. Muzzio DO, Soldati R, Rolle L, Zygmunt M, Zencussen AC, Jensen F. B-1a B cells regulate T cell differentiation associated with pregnancy disturbances. Front Immunol 2014; 5:56.
45. Hunt JS, Manning LS, Wood GW. Macrophages in murine uterus are immunosuppressive. Cell Immunol 1984; 85:499–510.
46. Svensson J, Jennmalm MC, Matsuske A, Geffers R, Berg G, Emerudh J. Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 2011; 187:3671–3682.
47. Svensson-Arvelund J, Mehta RB, Lindau R, Mirrasekhian E, Rodriguez-Martinez JH, Berg G, Lash GE, Jennmalm MC, Emerudh J. The human fetal placenta promotes tolerance against the semiallogeneic fetus by inducing regulatory T cells and homeostatic M2 macrophages. J Immunol 2015; 194:1534–1544.
48. Wan H, Versnel MA, Leijten LM, van Helden-Meeuwsen CG, Fekkes D, Leenen PJ, Khan NA, Benner R, Kiekens RC. Chorionic gonadotropin induces dendritic cells to express a tolerogenic phenotype. J Leukoc Biol 2008; 83:894–901.
49. Rao CV. Why are we waiting to start large scale clinical testing of human chorionic gonadotropin for the treatment of preterm births? Reprod Sci 2015; pii: 1933719115620498.
50. Braunstein GD, Rasor J, Danzer H, Adler D, Wade ME. Serum human chorionic gonadotropin levels throughout normal pregnancy. J Obstet Gynecol 1976; 126:678–681.
51. Edelstam G, Karlsson C, Westgren M, Lowbeer C, Swahn ML. Human chorionic gonadotropin (hCG) during trimester pregnancy. Scand J Clin Lab Invest 2007; 67:519–525.
52. Scholer H, Radnai D, Schmitt E, Mahake K, Sohn C, Steinborn A. Term and preterm labor: decreased suppressive activity and changes in composition of the regulatory T-cell pool. Immunol Cell Biol 2012; 90:935–944.
53. Bizgarty P, Del Rio R, Philipppe M, Teuscher C, Bonney EA. Resistance to lipopolysaccharide-induced preterm delivery mediated by regulatory T cell function in mice. Biol Reprod 2009; 80:874–881.
54. Arenas-Hernandez M, Romero R, St Louis D, Hassan SS, Kaye EB, Bizargity P, Del Rio R, Philipppe M, Teuscher C, Bonney EA. Resistance to lipopolysaccharide-induced preterm delivery mediated by regulatory T cell function in mice. Biol Reprod 2009; 80:874–881.
55. Rogers-Jones III, William J, Reigel J, Chaemsaithong P, Mahajan A, Gomez-Lopez N. Vaginal progesterone, but not 17alpha-hydroxyprogesterone caproate, has antiinflammatory and proregenerative effects at the murine maternal-fetal interface. J Leukoc Biol 2010; 88:625–633.
56. Erlebacher A. Immunology of the maternal-fetal interface. Annu Rev Immunol 2013; 31:387–411.
57. Xu Y, Romero R, Miller D, Kadam L, Miall TN, Plazyo O, Garcia-Flores V, Hassan SS, Xu Y, Tzara AL, Drewlo S, Gomez-Lopez N. An M1-like macrophage polarization in decidual tissue during spontaneous preterm labor that is attenuated by rosiglitazone treatment. J Immunol 2016; 196:2476–2491.
58. Bosu WT, Johansson ED. Effect of HCG on plasma levels of estrogens and progesterone during the luteal phase of the menstrual cycle in rhesus monkeys (Macaca mulatta): stimulation of sex steroid production in Rhesus monkeys. Int J Fertil 1974; 19:28–32.
59. Chaudhary J, Bhattacharya S, Das C. Regulation of progesterone secretion in human syncytiotrophoblast in culture by human chorionic gonadotropin. J Steroid Biochem Mol Biol 1992; 42:425–432.
60. Pretzer SD. Medical management of canine and feline dystocia. Theriogenology 2008; 70:332–336.
61. Rocheillon BL, Schulman H, Fleischer A, Farmakides G, Bracero L, Ducey J, Winter D, Penny B. The clinical significance of Doppler umbilical artery velocimetry in the small for gestational age fetus. Am J Obstet Gynecol 1987; 156:1223–1226.
62. ACOG technical bulletin. Fetal heart rate patterns: monitoring, interpretation, and management. Number 207–July 1995 (replaces No. 132, September 1989). Int J Gynaecol Obstet 1995; 51:65–74.
63. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otoku F, Sakaguchi S. Thymus and autostimulation: production of CD25 CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162:5317–5326.
64. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057–1061.
65. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4 CD25 regulatory T cells. Nat Immunol 2003; 4:330–336.
66. Khariti R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurf1 in CD4 CD25+ regulatory T cells. Nat Immunol 2003; 4:337–342.
67. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345–352.
68. Walker MR, Kasprowick DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. Induction of Foxp3 and acquisition of T regulatory activity by stimulated human CD4 CD25+ T cells. J Clin Invest 2003; 112:1437–1443.
69. Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD. Induction of Foxp3 and acquisition of T regulatory activity by stimulated human CD4 CD25+ T cells. J Clin Invest 2003; 112:1437–1443.
70. Robertson SA, Guerin LR, Frenkel MJ, Branson KM, Ahlstrom AC, Care AS. Seminal fluid drives expansion of the CD4 CD25+ regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod 2009; 80:1036–1045.
71. Shima T, Inada K, Nakashima A, Ushijma A, Itou M, Yoshino O, Saito S. Paternal antigen-specific proliferating regulatory T cells are increased in uterine-draining lymph nodes just before implantation and in pregnant uterus just after implantation by seminal plasma–priming in allogeneic mouse pregnancy. J Reprod Immunol 2015; 108:72–82.
72. Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory cell function. J Reprod Immunol 2015; 108:72–82.
73. Salhanick HA, Noall MW, Zarrow MX, Samuels LT. The isolation of progesterone from human placenta. Science 1952; 115:706–708.
74. Furcron AE, Romero R, Plazyo O, Unkel R, Xu Y, Hassan SS, Chaemsaithong P, Mahajan A, Gomez-Lopez N. Vaginal progesterone, but not 17alpha-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface. J Leukoc Biol 2015; 123:846 e841–846 e819.
75. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M1/M2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164:6166–6173.
76. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23–35.
77. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage...
plasticity and polarization in tissue repair and remodelling. J Pathol 2013; 229:176–185.

85. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010; 11: 889–896.

86. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab 2012; 15:432–437.

87. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJ, Cameron IT, Greer IA, Norman JE. Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum Reprod 1999; 14:229–236.

88. Mackler AM, Izaza G, Akin MR, McMillan P, Yellon SM. Macrophage trafficking in the uterus and cervix precedes parturition in the mouse. Biol Reprod 1999; 61:879–883.

89. Osman I, Young A, Ledgingham MA, Thomson AJ, Jordan F, Greer IA, Norman JE. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term. Mol Hum Reprod 2003; 9:41–45.

90. Gonzalez JM, Franzke CW, Yang F, Romero R, Girardi G. Complement leukocyte protease inhibitor in prelabor rupture of membranes, parturition and intra-amniotic infection. J Matern Fetal Neonatal Med 2012; 25:237–246.

91. Shishir SV, Kuklina EM, Yarlin AA. Reproductive hormones in the regulation of apoptosis of neutrophils. Biochemistry (Mosc) 2003; 68: 688–695.

92. Kuklina EM, Shishir SV. Role of cyclooxygenase in the choric gonadotropin regulation of human neutrophil activity. Bull Exp Biol Med 2009; 147:213–216.

93. Khil LY, Jun HS, Kwon H, Yoo JK, Kim S, Notkins AL, Yoon JW. Human choric gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice. Diabetologia 2007; 50:2147–2155.

94. Gomez-Lopez N, Vadillo-Ortega F. Specific inflammatory microenvironments in the zones of the fetal membranes at term delivery. J Langrish Gynecol 2011; 205:235 e215–e224.

95. Gomez-Lopez N, Vega-Sanchez R, Castillo-Castrejon M, Romero R, Cabezulo-Arreola K, Vadillo-Ortega F. Evidence for a role for the adaptive immune response in human term parturition. Am J Reprod Immunol 2013; 69:212–230.

96. Nakashima A, Ito M, Yoneda S, Shiozaki A, Hidaka T, Saito S. Circulating and decidual Th17 cell levels in healthy pregnancy. Am J Reprod Immunol 2010; 63:104–109.

97. Martinez-Garcia EA, Chavez-Robles B, Sanchez-Hernandez PE, Nunez-atahualpa L, Martin-Maguez BT, Munoz-Gomez A, Gonzalez-Lopez L, Gamez-Nava JI, Salazar-Paramo M, Davalos-Rodriguez I, Petri MH, Zungua-Tamayo D, et al. IL-17 increased in the third trimester in healthy women with term labor. Am J Reprod Immunol 2011; 65:99–103.

98. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133–1141.

99. Langrish CL, Chen Y, Blumentreich WM, Mattson I, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233–240.

100. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the Thelper type 1 and 2 lineages. Nat Immunol 2005; 6:1123–1132.

101. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 2006; 441: 235–238.

102. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the Th17 lineage. Nature 2006; 441:231–234.

103. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory Th17 cells. Nature 2007; 448:484–487.

104. Zhou L, Ivanov II, Spremusski R, Min R, Renderos K, Ewaga T, Levy DE, Leonard WJ, Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8:967–974.

105. van Hamburg JP, Asmanyadija PS, Daleelar N, Mus AM, Colin EM, Hazes JM, Dohlin R, Lubberts E. Th17 cells, but not Th1 cells, in patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63:73–83.

106. Ye F, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang F, Zhang J, Shellito JE, Bagby GJ, et al. Requirement of interleukin 17 receptor signaling for lung CXCR4 chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519–527.

107. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Huisain S, Kreindler JL, et al. IL-22...
mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14:275–281.
123. Kom T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27:485–517.
124. Ali AF, Fateen B, Ezzet A, Badawy H, Ramadan A, El-tobge A. Treatment of preterm labor with human chorionic gonadotropin: a new modality. Obstet Gynecol 2000; 95(suppl):S61.
125. Than NG, Itakura A, Rao ChV, Nohira T, Toth P, Mansell JP, Isaka K, Nishi H, Takayama M, Than GN. Clinical applications of pregnancy-related proteins—a workshop report. Placenta 2003; 24(suppl A): S60–64.
126. Kurtzman JT, Spinnato JA, Goldsmith LJ, Zimmerman MJ, Klem M, Lei ZM, Rao CV. Human chorionic gonadotropin exhibits potent inhibition of preterm delivery in a small animal model. Am J Obstet Gynecol 1999; 181:853–857.
127. Steele GL, Currie WD, Leung EH, Yuen BH, Leung PC. Rapid stimulation of human chorionic gonadotropin secretion by interleukin-1 beta from perfused first trimester trophoblast. J Clin Endocrinol Metab 1992; 75:783–788.
128. Seki H, Zosmer A, Elder MG, Sullivan MH. The regulation of progesterone and hCG production from placental cells by interleukin-1beta. Biochim Biophys Acta 1997; 1336:342–348.
129. Karagouni EE, Chryssikopoulos A, Mantzavinos T, Kanakas N, Dotsika EN. Interleukin-1beta and interleukin-1alpha may affect the implantation rate of patients undergoing in vitro fertilization-embryo transfer. Fertil Steril 1998; 70:553–559.
130. Banik UK. Pregnancy-terminating effect of human chorionic gonadotrophin in rats. J Reprod Fertil 1975; 42:67–76.
131. Mattheij JA, Heussen H, Linssen PC, Swarts JJ. The effect of a single dose of human chorionic gonadotropin at proestrus on embryonic mortality, fetal growth and gestation length in the rat. Gynecol Obstet Invest 1987; 24:107–113.
132. Jeyabalan A, Caritis SN. Pharmacologic inhibition of preterm labor. Clin Obstet Gynecol 2002; 45:99–113.
133. Caritis S. Adverse effects of tocolytic therapy. BJOG 2005; 112(suppl 1): 74–78.